- Zai Lab Announces Third Quarter 2023 Financial Results and Recent Corporate Updates
- Zai Lab Announces Participation in November Investor Conferences
- Zai Lab to Announce Third Quarter 2023 Financial Results and Recent Corporate Updates on November 7, 2023
- Zai Lab Obtains Breakthrough Therapy Designation for Efgartigimod Alfa Injection (Subcutaneous Injection) in Patients with Chronic Inflammatory Demyelinating Polyneuropathy in China
- Zai Lab Announces Breakthrough Therapy Designation Granted for Repotrectinib for Treatment of Patients with NTRK-positive TKI-pretreated advanced solid tumors in China
- Zai Lab Announces Participation in September Investor Conferences
- Zai Lab Announces Second Quarter 2023 Financial Results and Corporate Updates
- Zai Lab to Announce Second Quarter 2023 Financial Results and Corporate Updates on August 7, 2023
- JAMA Oncology Publishes Data from Zai Lab Study Demonstrating Significant Reduction in Disease Progression or Death with ZEJULA (Niraparib) Maintenance Therapy in Broad Population of Advanced Ovarian Cancer Patients
- Zai Lab and argenx Report Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy
More ▼
Key statistics
On Friday, Zai Lab Ltd (9688:HKG.HS) closed at 12.80, 21.21% above the 52 week low of 10.56 set on Apr 19, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 13.38 |
---|---|
High | 13.48 |
Low | 12.40 |
Bid | 12.76 |
Offer | 12.80 |
Previous close | 13.66 |
Average volume | 4.33m |
---|---|
Shares outstanding | 992.09m |
Free float | 897.16m |
P/E (TTM) | -- |
Market cap | 12.70bn HKD |
EPS (TTM) | -2.70 HKD |
Data delayed at least 15 minutes, as of May 03 2024.
More ▼